[go: up one dir, main page]

GB9911772D0 - Diagnosis and treatment of atherosclerosis - Google Patents

Diagnosis and treatment of atherosclerosis

Info

Publication number
GB9911772D0
GB9911772D0 GBGB9911772.3A GB9911772A GB9911772D0 GB 9911772 D0 GB9911772 D0 GB 9911772D0 GB 9911772 A GB9911772 A GB 9911772A GB 9911772 D0 GB9911772 D0 GB 9911772D0
Authority
GB
United Kingdom
Prior art keywords
atherosclerosis
diagnosis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9911772.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEMMELWEIS UNIVERSITY OF MEDIC
Original Assignee
SEMMELWEIS UNIVERSITY OF MEDIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SEMMELWEIS UNIVERSITY OF MEDIC filed Critical SEMMELWEIS UNIVERSITY OF MEDIC
Priority to GBGB9911772.3A priority Critical patent/GB9911772D0/en
Publication of GB9911772D0 publication Critical patent/GB9911772D0/en
Priority to EP00927636A priority patent/EP1179182A2/en
Priority to PCT/IB2000/000688 priority patent/WO2000072023A2/en
Priority to JP2000620360A priority patent/JP2003502289A/en
Priority to CN00807857A priority patent/CN1351713A/en
Priority to RU2001134499/14A priority patent/RU2001134499A/en
Priority to CA002373285A priority patent/CA2373285A1/en
Priority to BR0010741-7A priority patent/BR0010741A/en
Priority to HU0201568A priority patent/HUP0201568A2/en
Priority to AU46025/00A priority patent/AU4602500A/en
Priority to KR1020017014790A priority patent/KR20020022669A/en
Priority to ZA200109544A priority patent/ZA200109544B/en
Priority to NO20015653A priority patent/NO20015653L/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
GBGB9911772.3A 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis Ceased GB9911772D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB9911772.3A GB9911772D0 (en) 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis
KR1020017014790A KR20020022669A (en) 1999-05-21 2000-05-22 Diagnosis and Treatment of Atherosclerosis and Coronary Heart Disease
CA002373285A CA2373285A1 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
PCT/IB2000/000688 WO2000072023A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
JP2000620360A JP2003502289A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
CN00807857A CN1351713A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
RU2001134499/14A RU2001134499A (en) 1999-05-21 2000-05-22 DIAGNOSTICS AND TREATMENT OF ATHEROSCLEROSIS AND ISCHEMIC HEART DISEASE
EP00927636A EP1179182A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
BR0010741-7A BR0010741A (en) 1999-05-21 2000-05-22 hhsp60 or an immunogenic fragment thereof, diagnostic test method for a tendency to complement activation induced by heat shock protein, uses of hhsp60 and a member of the hsp60 protein family, other than hhsp60, and of antigen presenting an epitope unique for hhsp60 and that does not have any shared hsp60 epitopes, diagnostic test kit for patients who have a tendency to complement activation induced by heat shock protein, and methods of manufacturing a drug for the treatment of induced complement activation by heat shock protein, and to identify a compound or substance or agent that inhibits hhsp60-induced complement activation
HU0201568A HUP0201568A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
AU46025/00A AU4602500A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
ZA200109544A ZA200109544B (en) 1999-05-21 2001-11-20 Diagnosis and treatment of atherosclerosis and coronary heart disease.
NO20015653A NO20015653L (en) 1999-05-21 2001-11-20 Diagnosis and treatment of atherosclerosis and coronary heart disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911772.3A GB9911772D0 (en) 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
GB9911772D0 true GB9911772D0 (en) 1999-07-21

Family

ID=10853840

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9911772.3A Ceased GB9911772D0 (en) 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis

Country Status (13)

Country Link
EP (1) EP1179182A2 (en)
JP (1) JP2003502289A (en)
KR (1) KR20020022669A (en)
CN (1) CN1351713A (en)
AU (1) AU4602500A (en)
BR (1) BR0010741A (en)
CA (1) CA2373285A1 (en)
GB (1) GB9911772D0 (en)
HU (1) HUP0201568A2 (en)
NO (1) NO20015653L (en)
RU (1) RU2001134499A (en)
WO (1) WO2000072023A2 (en)
ZA (1) ZA200109544B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
ES2315034B1 (en) * 2004-07-02 2009-12-30 Laboratorios Indas, S.A. THERMAL SHOCK PROTEIN 27 (HSP-27) AS A CARDIOVASCULAR DISEASE MARKER.
CU23504A1 (en) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
JP4283812B2 (en) * 2006-01-06 2009-06-24 財団法人工業技術研究院 Diagnostic method of myasthenia gravis and its kit
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
RU2341801C2 (en) * 2006-11-28 2008-12-20 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Method of antihypertensive therapy efficiency evaluation in patients suffering from essential hypertension
JP4581094B2 (en) * 2006-12-07 2010-11-17 国立大学法人 岡山大学 Testing method for arteriosclerosis
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
KR102344948B1 (en) * 2018-09-03 2021-12-28 세종대학교산학협력단 Monoclonal antibody N1-A4 specific to human naive pluripotent stem cells
RU2760539C1 (en) * 2021-02-07 2021-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пензенский государственный университет" Method for screening diagnosis of coronary atherosclerosis using non-invasive ca-biomarker
WO2024017423A1 (en) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Peptide for the treatment of diseases associated with apolipoprotein ai or transthyretin involvement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398495B (en) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnosis or prognosis of atherosclerosis
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity

Also Published As

Publication number Publication date
RU2001134499A (en) 2003-08-27
CN1351713A (en) 2002-05-29
HUP0201568A2 (en) 2002-08-28
WO2000072023A2 (en) 2000-11-30
NO20015653L (en) 2002-01-17
BR0010741A (en) 2002-02-19
AU4602500A (en) 2000-12-12
NO20015653D0 (en) 2001-11-20
EP1179182A2 (en) 2002-02-13
WO2000072023A3 (en) 2001-04-05
KR20020022669A (en) 2002-03-27
JP2003502289A (en) 2003-01-21
ZA200109544B (en) 2002-06-20
CA2373285A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
GB9903841D0 (en) Diagnosis and treatment of cancer
GB2368794B (en) Prevention and treatment of amyloidogenic disease
HUP0201205A3 (en) Prevention and treatment of amyloidogenic disease
PL350822A1 (en) Disposable wiper-cloth and method of making same
GB9824436D0 (en) Methods of treatment
IL149251A0 (en) Diagnosis and treatment of cardiovascular conditions
PL350826A1 (en) Disposable wiper-cloth and method of making same
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
IL138692A0 (en) Treatment and prevention of vascular disease
GB9811598D0 (en) Diagnosis and treatment of cancer
HUP0201966A3 (en) Methods of treatment and drug screening methods
GB2381272B (en) Diagnosis and treatment of atherosclerosis
GB9908059D0 (en) Diagnosis and treatment of diseases
GB2343629B (en) Treatment of cellulite
AU1654001A (en) Improved physical and thermal treatment of waste
HUP0300043A3 (en) Method and composition for the treatment of pain
IL133038A0 (en) Novel diagnosis and treatment for atherosclerosis
IL150208A0 (en) Compound and method for the treatment of pain
AU2002321525A1 (en) Diagnosis and treatment of atherosclerosis
GB9914589D0 (en) Diagnosis and treatment of alzheimers diease
TW552939U (en) Improved structure of case for steam and medical bath
GB9901310D0 (en) Methods of treatment
GB9917181D0 (en) Methods of treatment
GB9726745D0 (en) Treatment of medical conditions
GB9901904D0 (en) RTherapeutic use of human pheramones

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)